Description

Reltecimod TFA, also known by its investigational code AB-103, is a synthetic peptide antagonist of the T-cell co-stimulatory receptor CD28 (TP44). Crafted under GMP-compliant processes, this peptide—boasting 99.78% purity—has demonstrated potent modulation of immune responses in preclinical and clinical studies. It attenuates the CD28/B7-2 co-stimulatory signaling axis, helping to mitigate excessive inflammatory cascades while preserving necessary immune function.

In preclinical murine infection models, a single dose of Reltecimod significantly increased survival, lowered pro-inflammatory cytokine surges, and improved outcomes compared to repetitive dosing.

In a Phase 3 clinical trial involving patients with necrotizing soft-tissue infections (NSTI), early administration of Reltecimod enhanced resolution of organ dysfunction and improved clinical outcomes, particularly in per-protocol analysis.

Reltecimod TFA Product Specifications

Reltecimod TFA Mechanism of Action & Research Applications

Mechanism of Action
Reltecimod targets CD28/B7-2 co-stimulation on T cells, moderating T-cell activation without full inhibition. This fine-tuned modulation helps dampen overwhelming cytokine responses to bacterial pathogens, exotoxins, endotoxins, and radiation-induced injury.

Research Applications

• Necrotizing Soft-Tissue Infection (NSTI) Models — Promotes resolution of organ dysfunction and improved clinical outcomes when administered early.

• Preclinical Infection Studies — Single-dose regimens in lethal infection models yield improved survival and reduced cytokine storm.

• Inflammation Modulation — Provides a tool to study immune attenuation mechanisms in models of septic shock, bacterial infection, and radiation injury.

• Immunological Signaling Research — Unravels the balance between T-cell activation and suppression via CD28-dependent pathways.

Reltecimod TFA Development & Formulation Notes

• Reconstitution: Dissolve in DMSO to prepare concentrated stocks (e.g., 5–10 mg/mL). Dilute into buffer immediately before use.

• Storage & Aliquoting: Store aliquots at –80 °C for long-term stability; avoid multiple freeze-thaw cycles.

• Assay Guidance: In infection and organ dysfunction models, proactive administration (e.g., within 6 hours post-diagnosis) yields optimal outcomes. Use single-dose protocols for best efficacy, per preclinical findings.

  

Disclaimer

Reltecimod TFA is supplied strictly for laboratory research use only. It is not a pharmaceutical, therapeutic agent, or diagnostic product and is not approved for human or veterinary use. Handle under proper biosafety protocols and dispose of materials according to local regulations. Users are responsible for confirming suitability and compliance within their research settings.

Reltecimod TFA Packaging & Availability

• Standard Packs: 2 mg, 5 mg, or 10 mg

• Bulk/Wholesale: Multi-gram availability with batch consistency and reserved supply
  Each shipment includes a Certificate of Analysis (CoA) verifying purity, identity, and handling guidelines.

Quality Assurance

Manufactured under strict GMP standards. Each batch is validated using mass spectrometry (MS), high-performance liquid chromatography (HPLC), and stability tests. Lot-specific documentation is provided to support research integrity and possible audit requirements.

Custom Services

• Aliquoting & Custom Labeling: Fitment for LIMS or ELN systems.

• Formulation Support: Guidance on buffer systems and DMSO-based stock solutions.

• Stability Study Design: Consultation for storage and transportation planning.

• Experimental Strategy Support: Optimization for NSTI, cytokine storm, or immunomodulatory models.

Keywords

Reltecimod TFA; AB-103 TFA; CD28 antagonist peptide; necrotizing soft tissue infection research; NSTI immunomodulator; cytokine storm peptide; GMP peptide; CD28/B7-2 pathway; infection model peptide; research-use-only.